Prevail Therapeutics lands $75 mln Series A

New York City-based Prevail Therapeutics Inc, a developer of gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, has secured $75 million in Series A financing. The investors included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.

Source: Press Release